Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study
| Autor: | Takafumi Tsuchiya, Tatsuhiko Suzuki, Toshihiko Inukai, Rika Naruse, Kohzo Takebayashi, Kenji Hara, Mariko Suetsugu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
business.industry Type 2 diabetes 030209 endocrinology & metabolism General Medicine 030204 cardiovascular system & hematology medicine.disease Repaglinide Durability 03 medical and health sciences Hba1c level 0302 clinical medicine Endocrinology Internal medicine medicine Original Article Observational study Term effect business Pioglitazone Alogliptin medicine.drug Glycemic |
| Zdroj: | Journal of Clinical Medicine Research |
| ISSN: | 1918-3011 1918-3003 |
| DOI: | 10.14740/jocmr3118w |
| Popis: | Background: The goal of the current study was to investigate the long-term effects (after 3 years or more) of alogliptin on glycemic control in Japanese patients with type 2 diabetes. Methods: We retrospectively studied the effect of alogliptin on glycemic control in the patients with type 2 diabetes who had participated in our previous 3-month study and who continued to take alogliptin for at least 36 months. Results: The mean duration of alogliptin treatment was 42.8 ± 2.2 months. In all 39 patients, a significant reduction in hemoglobin A1c (HbA1c) levels was noted between the baseline and final visit: 7.8±0.6% to 7.2±1.0% (P = 0.0001). A significant reduction in HbA1c levels was found in a subgroup of patients who did not change their anti-diabetic drugs or did decrease the dose of their sulfonylureas (SUs) or did change to a lower strength repaglinide (n = 32): 7.7±0.6% to 7.2±1.0% (P = 0.0005). A significant decrease in low-density lipoprotein cholesterol (LDL-C) levels was observed in all of the patients that had LDL-C levels determined (P = 0.0406) (n = 37), and in a subgroup of patients who had not taken either statins, fibrates, or pioglitazone, or who had taken one or more of these drugs but the doses were not changed during the observation period (P = 0.0250) (n = 27). Conclusion: The current study found that alogliptin performed well for glycemic control when evaluated by HbA1c levels in a long-term observation period exceeding 3 years in Japanese patients with type 2 diabetes. Alogliptin may also decrease circulating LDL-C levels with long-term use. J Clin Med Res. 2017;9(9):802-808 doi: https://doi.org/10.14740/jocmr3118w |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|